iLASIK vision correction combines AMO technologies

Article

Advanced Medical Optics (AMO) continues its commitment to the LASIK industry by reaching out to a generation of nearly 290 million people worldwide who want better everyday vision.

Advanced Medical Optics (AMO) continues its commitment to the LASIK industry by reaching out to a generation of nearly 290 million people worldwide who want better everyday vision (iLASIK vision correction).

The iLASIK procedure is a consumer-facing brand platform that communicates the advantage of two of the company's technologies: femtosecond flap creation technology (IntraLase FS) and custom laser vision correction (Advanced CustomVue). The company presented the re-branded LASIK procedure during a user group meeting at the Hilton Riverside Hotel here prior to the American Academy of Ophthalmology annual meeting.

According to Ron Bache, global vice president of marketing, AMO refractive surgery, the procedure:

•Provides one integrated platform that features advanced technology at every step.

•Can be actively marketed to all segments of "Generation i" (college students, baby boomers, and even fighter pilots).

•Establishes the company as a committed partner that is making an unmatched investment in LASIK.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.